Investor NB Public Equity K/S
13D/G Filings

This page shows a list of all the recent 13D/G filings made by NB Public Equity K/S . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2020-01-21 13G/A NVLN / NOVELION THERAPEUTICS INC. 1,890,525 0
2018-12-17 13G/A NVLN / NOVELION THERAPEUTICS INC. 1,890,525 1,890,525
2018-11-19 13G NVLN / NOVELION THERAPEUTICS INC. 1,289,525 1,890,525
2018-05-04 13G ALDR / Alder BioPharmaceuticals, Inc. 3,419,954
2017-01-31 13G/A CTIC / CTI BioPharma Corp 12,666,354 13,566,354
2016-12-22 13D/A NVLN / NOVELION THERAPEUTICS INC. 1,289,525
2016-01-29 13G CTIC / CTI BioPharma Corp 12,666,354
2014-07-15 13D/A NVLN / NOVELION THERAPEUTICS INC. 6,447,626
2012-06-05 13D/A NVLN / NOVELION THERAPEUTICS INC. 7,447,626
2012-05-22 13D NVLN / NOVELION THERAPEUTICS INC. 7,447,626
2012-03-29 13G/A NVLN / NOVELION THERAPEUTICS INC. 7,397,626